Fleury’s Stock Forecast: A Closer Look at Rising Recommendations

Recently, Fleury (FLRY3) experienced a notable uplift in market approval. Itaú BBA’s initial affirmation prompted Santander and BTG Pactual to upgrade to a “buy” rating.

Santander predicts a revenue upswing due to timely calendar effects, enhancements in the lab-to-lab (L2L) operations, and a balanced competitive arena.

They expect a rise in profits and deem the current stock valuation fair. Highlighting Fleury’s robust, cash-generating structure underpins its suitability amidst economic fluctuations.

Santander keeps its leverage forecast low, with a steady net debt/equity ratio of 1.2. Cash flow yields are projected at 6.7% for 2024 and 7.2% for 2025.

In addition, they argue the L2L segment’s growth at a 12% annual rate from 2024 to 2027 remains overlooked, pivotal for Fleury’s revenue advancement.

Fleury’s shares are priced at 9.8 times earnings for 2025, suggesting a bargain against the three-year average of 14 times.

BTG Pactual acknowledges Fleury as a resilient pick during market turmoil, credited to its predictable and stable diagnostic services.

Additionally, the firm appreciates Fleury’s minimal debt and strong cash flow (8.5% in 2024, and 11% in 2025).

Uncovering Fleury’s Potential

Despite its high market share, only a few investors recognize it as the top long-term health sector bet.

BTG underscores the solid foundation of Fleury’s investment logic. The company has increased its market presence through strategic execution where competitors faltered.

Fleury has also broadened into new areas, growing from 1% to 9% of total revenues over the past the past three years. BTG foresees these shifts as enduring.

The merger with Pardini went smoothly, incorporating a few one-time items in Q2 2023. Synergy efforts continue, boosting operational margins.

However, this narrative of upgrades and optimism is set against the backdrop of an evolving healthcare landscape where diagnostic services play a crucial role.

Fleury’s strategic expansions and consistent financial health indicate its ability to thrive in uncertain times.

In short, this makes it a noteworthy consideration for investors seeking stability in a sector vital to global well-being.

Related coverage: Dollar Climbs to R$ 5.58 Amid Lula's Remarks and Ptax Tensions · Fitch Maintains Brazil's "BB" Rating with Stable Outlook · Ibovespa Closes Lower Amid Lula's Criticism and Global Concerns · Latin America's Economic Trends This Week

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.